Medical technology companies rarely produce dramatic headlines, and that is usually the point. Their appeal lies in steady Demand for products that patients use every day, from ostomy bags to insulin pump sets. Convatec's latest update fits that pattern, but with a twist: the group is asking the market to look past a soft headline number to a stronger second half.
Convatec (LSE:CTEC), the FTSE 100 constituent that specialises in chronic care products, published interim results on 4 August 2026. Organic growth excluding its troubled InnovaMatrix wound product was 5.0%, and the company narrowed its full-year guidance while pointing to 6% to 8% growth in the second half. It also launched a $200m share buyback.
A first half of two stories
The first half contained a solid core Business and one clear problem. Excluding InnovaMatrix, organic Revenue growth was 5.0%. Including it, the figure drops to 1.8%, and reported growth was 4.4%. First-half revenue was about $1.23bn.
Chief executive Jonny Mason said the group had delivered "further broad-based and resilient growth". The category split backs that up. Infusion Care grew 7.4% organically, Continence Care 5.9%, Ostomy Care 4.3% and Advanced Wound Care 3.4% excluding InnovaMatrix. Infusion Care, which supplies disposable sets for insulin pumps and continuous therapies including treatments for Parkinson's disease, is roughly a fifth of group revenue and is the division leading the expected acceleration.
The InnovaMatrix hit and what the guidance now says
InnovaMatrix is a skin substitute product used in wound care, and its Economics changed sharply after a US reimbursement cut. Convatec said the Medicare rate fell by 85% to $127 per square centimetre. First-half InnovaMatrix revenue fell 94% to $2.5m, and the company took a $69m non-cash impairment.
For the full year, InnovaMatrix revenue is now expected at about $5m to $10m, down from about $20m previously, representing a headwind of roughly 2.5% to group revenue. Excluding the product, Convatec narrowed its 2026 organic growth guidance to 5.5% to 6.5%, from 5% to 7%, which implies second-half growth of 6% to 8%.
Profitability guidance was left unchanged. The adjusted Operating Margin in the first half was 21.2%, 10 basis points lower than a year earlier but 50 basis points higher at constant currency. The full-year target is at least 23.0%, including about 40 basis points of currency benefit, which requires a materially higher margin in the second half. The group also reiterated double-digit adjusted Earnings Per Share growth and cash conversion of around 100%.
Returns to shareholders and the balance sheet
Adjusted Diluted Earnings per Share rose 6.3% to 8.5 cents, while reported diluted earnings per share, weighed down by the impairment, were 2.7 cents. The Interim Dividend was lifted by 15% to 2.166 cents.
The $200m buyback, due to be completed by the end of 2026, signals confidence in cash generation. Regular filings since August show repurchases under way. However, the Balance Sheet is somewhat more stretched than a year ago. Net Debt was $1,534m, equal to 2.3 times adjusted EBITDA compared with 1.9 times previously, and free Cash Flow available to shareholders before growth Capital Expenditure was only $22m in the half. Delivering the promised second-half cash generation will therefore matter.
Why the second half is so important
Convatec's Investment case rests on moving from a period of repair to one of consistent, above-market growth. Under its Accelerate strategy, from 2027 the company is targeting organic revenue growth of 6% to 8% a year, an adjusted operating margin of 24% to 26%, and double-digit growth in both adjusted earnings per share and free cash flow available to shareholders.
A second half that grows at 6% to 8% would effectively show the business already running at the medium-term rate. That would give credibility to the targets and help separate the core Franchise from the InnovaMatrix setback. Management expects six new chronic-care product launches in 2026 and eight across 2026 and 2027, which should support growth in categories such as continence and infusion care.
The wider sector backdrop is mixed. Medical technology groups face Tariff uncertainty, reimbursement pressure in the US and cost Inflation in raw materials. Chronic care is less cyclical than elective surgery, but it is not immune to pricing pressure from payers.
Risks that could derail the plan
The most obvious risk is execution. Guidance for the year depends on a stronger second half in both growth and margins, and any slippage would leave the company short of its targets. Back-end loaded guidance is common in the sector, but it leaves less room for error.
Regulatory risk remains in view. Convatec is working through remediation related to an FDA Warning Letter, which it says has no patient safety impact, but such matters can take time and money to resolve. The InnovaMatrix episode also shows how quickly a US reimbursement decision can change the value of a product.
Costs are another watch point. The company has noted limited cost inflation linked to conflict in the Middle East, and in May it cautioned that higher raw material costs could affect profitability in 2027. Leverage at 2.3 times is manageable, but combined with a buyback it reduces flexibility if trading weakens.
Milestones on the calendar
The next significant update is likely to be a trading statement covering the third quarter or the run-in to year end, followed by full-year results in early 2027. Those figures will show whether second-half organic growth reached the 6% to 8% range and whether the operating margin cleared 23%.
Other things to watch include the pace of the $200m buyback, progress on the FDA remediation, the timing of new product launches and any further change to US reimbursement for wound care products. Early 2027 will also mark the formal start of the medium-term targets, so any commentary on the year ahead will be closely examined.
Conclusion
For Convatec (LSE:CTEC), the interim results showed a resilient core business, rising dividends and a new buyback, set against the sharp collapse in InnovaMatrix sales and higher leverage. The narrowed guidance hinges on a stronger second half, which would lend weight to the group's ambitious medium-term goals. If that acceleration arrives, the InnovaMatrix setback may look like a one-off; if it does not, confidence in the targets could be tested.






Please wait processing your request...